Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fra…
Biotechnology
US, New York [HQ]
Cash Flow Statements
6 Sheets · Starting from 2024In Million USD. Margins, Growth Rates In %
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Operating Cash Flow (OCF) | - - | -53.00 | -83.00 | -106.00 | -188.00 | -214.00 | |
| Operating Cash (Net) | - - | -53.00 | -83.00 | -106.00 | -188.00 | -214.00 | |
| Accounts Receivable | - - | - - | - - | -11.00 | 11.00 | -4.00 | |
| Accounts Payable | - - | - - | 1.00 | 16.00 | -17.00 | 5.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | |
| Change | - - | 4.00 | 4.00 | 15.00 | -10.00 | 2.00 | |
| Other WC | - - | 3.00 | 3.00 | 10.00 | 5.00 | 1.00 | |
| Investing Activities | |||||||
| Used Cash (Net) | - - | - - | - - | - - | - - | - - | |
| Capital Expenditure | - - | - - | - - | - - | - - | - - | |
| Purchases of Investments | - - | - - | - - | - - | - - | - - | |
| Sale/Maturity of Investment | - - | - - | - - | - - | - - | - - | |
| Property, Plant, Equipment (P&PE) | - - | - - | - - | - - | - - | - - | |
| Acquisitions (Net) | - - | - - | - - | - - | - - | - - | |
| Other Investing Activities | - - | - - | - - | - - | - - | - - | |
| Financing Activities | |||||||
| Used Cash (Net) | - - | -146.00 | -383.00 | -200.00 | -70.00 | -472.00 | |
| Debt Repayment | - - | -5.00 | -3.00 | - - | - - | - - | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | - - | - - | - - | |
| Issued | - - | -1.00 | 319.00 | - - | 70.00 | 472.00 | |
| Repurchased | - - | - - | - - | - - | - - | - - | |
| Other Financing Activities | - - | 153.00 | 66.00 | 200.00 | - - | -6.00 | |
| Cash Balances | |||||||
| Begin of Period | - - | 6.00 | 100.00 | 400.00 | 493.00 | 376.00 | |
| End of Period | - - | 100.00 | 400.00 | 493.00 | 376.00 | 635.00 | |
| Change | - - | 93.00 | 299.00 | 93.00 | -117.00 | 258.00 | |
| Non-Cash Balances | |||||||
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | |
| Stock Based Compensation | - - | 6.00 | 18.00 | 34.00 | 32.00 | 41.00 | |
| Other | - - | 1.00 | - - | 1.00 | 1.00 | 41.00 | |
| Highlighted metrics | |||||||
| Free Cash Flow (FCF) | - - | -53.00 | -83.00 | -106.00 | -188.00 | -214.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | - - | - - | - - | - - | |
| Invested Capital | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
|||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - |